Inhibition of either the CCR-5 or IL-6 receptor resulted in decreased tumor growth and metastatic spread [34], suggesting that there are three points of potential therapeutic intervention in this pathway (STAT3, IL-6, or CCR-5) for TNBC. The gene discussed is CCR5; the disease is neoplasm.